Moran Wealth Management LLC Lowers Stock Holdings in Cencora, Inc. $COR

Moran Wealth Management LLC cut its stake in shares of Cencora, Inc. (NYSE:COR) by 9.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,824 shares of the company’s stock after selling 6,436 shares during the period. Moran Wealth Management LLC’s holdings in Cencora were worth $18,479,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kemnay Advisory Services Inc. purchased a new stake in shares of Cencora during the fourth quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new position in Cencora during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the 4th quarter worth $27,000. Archer Investment Corp boosted its holdings in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora in the fourth quarter valued at about $29,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of NYSE:COR opened at $296.43 on Friday. The firm has a market capitalization of $57.67 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 1.65 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business’s 50 day simple moving average is $277.91 and its 200-day simple moving average is $320.37. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the previous year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has authorized a share buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Insider Activity

In other news, Director Lauren M. Tyler purchased 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.38% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

COR has been the subject of several analyst reports. William Blair initiated coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Morgan Stanley set a $342.00 price target on Cencora in a research note on Friday, May 8th. Robert W. Baird cut their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.